시장보고서
상품코드
2129011

플라스미드 DNA 제조 시장 : 등급별, 개발 단계별, 용도별, 질환별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Plasmid DNA Manufacturing Market, By Grade, By Development Phase, By Application, By Disease, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

발행일: | 리서치사: 구분자 AnalystView Market Insights | 페이지 정보: 영문 361 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




가격
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.
US $ 3,250 금액 안내 화살표 ₩ 4,433,000
PDF (5 User License) help
PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,560 금액 안내 화살표 ₩ 6,220,000
PDF & Excel (Enterprise User License) help
PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 5,650 금액 안내 화살표 ₩ 7,707,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

플라스미드 DNA 제조 시장 규모는 2025년에 24억 7,852만 달러로 평가되었고, 2026-2033년 CAGR 17.98%로 성장할 전망입니다.

플라스미드 DNA 제조란, 제어된 생물학적 공정 및 정제 공정을 이용하여 이중가닥 DNA의 고리형 구조를 가진 DNA 분자인 플라스미드를 생산하는 것을 의미합니다. 플라스미드 DNA는 주로 유전자 치료, DNA 백신, 세포 및 유전자 치료, 재조합 단백질 및 기타 연구 목적으로 생산됩니다. 플라스미드 DNA 제조 공정에는 플라스미드의 설계 및 클로닝, 대장균 등의 박테리아로의 형질전환, 플라스미드 수를 늘리기 위한 발효, 수확, 세포 용해, DNA 정제, 그리고 시험 및 품질 관리가 포함됩니다. 다만, 임상 및 상업적 용도의 경우, 제조되는 플라스미드 DNA가 정해진 품질 기준을 충족하도록 GMP 조건 하에서 제조 공정이 수행됩니다.

플라스미드 DNA 제조 시장 : 시장 역학

확대되는 유전자·세포 치료제 파이프라인이 시장 성장을 주도

유전자·세포 치료 파이프라인의 급속한 확대는 플라스미드 DNA 제조 시장의 주요 촉진요인이 되고 있습니다. 플라스미드 DNA는 AAV 및 렌티바이러스 벡터를 포함한 여러 바이러스 벡터의 제조 공정에서 필수적인 구성 요소이며, 일부 유전자 치료에서도 직접 사용되고 있습니다. Cogentia에 따르면, 2024년 말 기준으로 유전자 치료 파이프라인에는 전임상 단계의 후보가 약 1,424건,1상 임상시험 단계의 후보 341건, 2상 임상시험 단계의 후보 306건, 3상 임상시험 단계의 후보 35건이 포함되어 있어, 임상 및 상업 생산 단계에 진입하는 프로그램이 다수 존재함을 시사하고 있습니다. 이러한 치료법이 임상 단계를 거치면서, 개발 기업들은 고품질의 GMP 등급 플라스미드 DNA를 점점 더 대량으로 필요로 하고 있습니다.

2025년의 주요 파이프라인 프로그램은 플라스미드 DNA 제조 시장의 중요한 견인차 역할을 할 것입니다. Vertex Pharmaceuticals의 CASGEVY(exagamglogene autotemcel)는 주요 유전자 편집 치료법이며, Sarepta Therapeutics의 ELEVIDYS(delandistrogene moxeparvovec)는 시판 중인 AAV 기반 치료법입니다. 이들 모두는 FDA의 승인된 세포 및 유전자 치료 제품 목록에 포함되어 있습니다. 이러한 치료법이 지속적으로 발전함에 따라, 바이러스 벡터 제조 공정에 사용되는 플라스미드 DNA에 대한 다운스트림 공정 수요가 발생할 것입니다.

플라스미드 DNA 제조 시장 : 시장 세분화 분석 :

세계 플라스미드 DNA 제조 시장은 등급, 개발 단계, 용도, 질환 및 지역을 기준으로 세분화됩니다.

시장은 개발 단계에 따라 전임상 단계 치료제, 시판 치료제, 임상 단계 치료제의 3가지 범주로 분류됩니다. 임상 단계 치료제 부문은 플라스미드 DNA 제조 시장에서 상당한 매출 성장이 예상됩니다. 이 부문의 견고한 매출 전망은 주로 전임상 개발 단계에 진입한 후 제1-3상 임상시험으로 진행되는 치료제 후보의 수가 증가하고 있기 때문입니다. 유전자 치료 제조 공정에 사용되는 임상용 플라스미드는 바이러스 벡터 생산, 유전자 편집 또는 직접적인 치료 성분으로서 수요가 점점 더 높아지고 있습니다. 고품질이면서 GMP(의약품 제조 관리 및 품질 관리 기준)를 준수하는 플라스미드 DNA에 대한 수요 증가는 후기 임상시험에서 사용되는 플라스미드의 일관된 대규모 생산에 대한 수요 증가와도 관련이 있습니다.

시장은 질환에 따라 유전성 질환, 암, 감염증, 기타 4가지 범주로 분류됩니다. 암 부문은 가장 높은 매출 성장이 예상됩니다. 이러한 현저한 매출 성장은 암 유전자 치료, 세포 치료, 바이러스 벡터 제조 및 DNA 기반 암 백신 분야에서 플라스미드 DNA의 채택 확대에 의해 주도되고 있습니다. 플라스미드 DNA는 바이러스 벡터 제조 및 현대 종양 치료에 활용되는 세포의 유전자 변형에 있어 중요한 출발 물질입니다. 고순도 및 GMP 등급 플라스미드 DNA에 대한 수요는 제약사 및 생명공학 기업들의 암 분야 유전자 치료 및 세포 치료 파이프라인 확장에 힘입어 증가하고 있습니다. 특히, 후보 약물이 전임상 연구에서 임상시험 및 상업적 생산 단계로 넘어감에 따라 그 수요는 증가하고 있습니다. 또한, 맞춤형·표적형 암 치료제의 사용 증가도 이러한 수요를 뒷받침하고 있습니다.

플라스미드 DNA 제조 시장 : 지역별 분석

북미가 시장을 독점하고 있습니다. 주요 성장 요인 중 하나는 암의 부담이 심각해지고 증가하고 있다는 점, 그리고 제조 공정에서 플라스미드 DNA를 중요한 원료로 사용하는 유전자 치료, 세포 치료, 암 백신 및 기타 신규 생물학적 제제에 대한 관심이 높아지고 있다는 점입니다. 미국 국립암연구소(NCI)의 추산에 따르면, 2025년에는 미국에서 204만 1,910건의 신규 암 사례와 61만 8,120명의 암 사망자가 발생할 것으로 예측됩니다. 한편, 캐나다 암 통계(Canadian Cancer Statistics)에 따르면, 2025년에는 캐나다에서 25만 4,800건의 신규 암 사례와 8만 7,400명의 암으로 인한 사망이 발생할 것으로 예측됩니다. 이러한 막대한 암 부담으로 인해 제약 회사와 생명공학 기업들은 암 치료에 특화된 유전자·세포 치료제 파이프라인을 확대하고 있으며, 그 결과 바이러스 벡터 제조 및 유전공학 분야에서 고순도 GMP 등급 플라스미드 DNA에 대한 수요가 증가하고 있습니다.

미국 플라스미드 DNA 제조 시장 : 국가별 분석

미국이 시장 점유율의 대부분을 차지하고 있습니다. 이러한 성장의 주요 촉진요인 중 하나는 주요 제약 및 생명공학 기업들의 유전자·세포 치료제 개발 및 제조에 대한 막대한 투자이며, 이는 바이러스 벡터 생산 및 유전공학 분야에서 필수적인 구성 요소인 고품질 플라스미드 DNA에 대한 수요 증가로 이어지고 있습니다. 예를 들어, 노바티스는 2025년 4월, 첨단 치료법을 지원하는 역량 확충을 포함하여 미국 내 제조 및 연구개발 거점에 5년간 230억 달러를 투자하겠다고 발표했습니다. 이 회사의 미국 네트워크에는 이미 노스캐롤라이나주 더럼에 위치한 유전자 치료용 제조 시설이 포함되어 있습니다.

목차

제1장 플라스미드 DNA 제조 시장 개요

제2장 주요 요약

제3장 플라스미드 DNA 제조 주요 시장 동향

제4장 플라스미드 DNA 제조 산업 분석

제5장 플라스미드 DNA 제조 시장 : 높아지는 지정학적 긴장의 영향

제6장 플라스미드 DNA 제조 시장 구도

제7장 플라스미드 DNA 제조 시장 : 등급별

제8장 플라스미드 DNA 제조 시장 : 개발 단계별

제9장 플라스미드 DNA 제조 시장 : 용도별

제10장 플라스미드 DNA 제조 시장 : 질환별

제11장 플라스미드 DNA 제조 시장 : 지역별

제12장 주요 벤더 분석 : 플라스미드 DNA 제조 산업

제13장 AnalystView 전방위 전망

AJY 26.09.17

Plasmid DNA Manufacturing Market size was valued at US$ 2,478.52 Million in 2025, expanding at a CAGR of 17.98% from 2026 to 2033.

Plasmid DNA Manufacturing means the production of plasmids, which are DNA molecules in the form of circles of double-stranded DNA, by means of controlled biological and purification processes. Plasmid DNA is mostly produced for gene therapy, DNA vaccination, cell and gene therapy, recombinant proteins, and another research. The process of plasmid DNA manufacturing includes plasmid design and cloning, transformation of bacteria such as Escherichia coli and fermentation to increase the number of plasmids, harvesting, cell lysis, DNA purification, and testing and quality control. However, for clinical and commercial application, the process of manufacturing is carried out under GMP conditions to ensure compliance with the needed quality of the produced plasmid DNA.

Plasmid DNA Manufacturing Market- Market Dynamics

Growing gene and cell therapy pipeline drives market growth

The rapid expansion of gene and cell therapy pipelines is a major driver for the plasmid DNA manufacturing market. Plasmid DNA is an essential component in the manufacturing process of several viral vectors, including AAV and lentiviral vectors and is also used directly in some gene therapies. By the end of 2024, the gene-therapy pipeline contained approximately 1,424 preclinical candidates, 341 Phase I candidates, 306 Phase II candidates, and 35 Phase III candidates, suggesting there is a large pool of programs that will be entering clinical and commercial manufacturing, according to the Cogentia. As these therapies progress through the clinical phases, developers require increasing quantities of high-quality and GMP-grade plasmid DNA.

Leading pipeline programs in 2025 will be important drivers for the plasmid DNA manufacturing market. Vertex Pharmaceuticals's CASGEVY (exagamglogene autotemcel) is a major gene-editing therapy, while Sarepta Therapeutics's ELEVIDYS (delandistrogene moxeparvovec) represents a commercial AAV-based therapy; both are included in the FDA's list of approved cellular and gene therapy products. As such therapies continue to progress, there will be downstream requirements for plasmid DNA for use in the manufacturing process of viral vectors.

Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Plasmid DNA Manufacturing Market is segmented on the basis of grade, development phase, application, disease, and Region.

The market is divided into three categories based on development phase: Pre-Clinical Therapeutics, Marketed Therapeutics and Clinical Therapeutics. The Clinical Therapeutics sector is expected to observe significant revenue growth in the Plasmid DNA Manufacturing market. The strong revenue outlook of the segment is primarily attributed to the rising number of therapeutic candidates entering pre-clinical development and subsequently progressing towards phase I-III clinical trials. Clinical grade plasmids, which are used in the manufacturing process of gene therapies, are increasingly in demand in connection with the production of viral vectors, gene-editing, or as a direct therapeutic moiety. The greater need for plasmid DNA of higher quality and compliance (GMP) is also linked to the greater need for consistent and large-scale production of plasmids for use in later-stage clinical trials.

The market is divided into four categories based on disease: Genetic Disorder, Cancer, Infectious Disease and Others. The Cancer segment would witness the highest revenue growth. The significant revenue growth is driven by the rising adoption of plasmid DNA in cancer gene treatments, cell therapies, viral-vector production and DNA-based cancer vaccinations. Plasmid DNA is a key starting material for the production of viral vectors and for the genetic modification of cells utilized in modern oncology therapies. The demand for high-purity and GMP-grade plasmid DNA is being driven by the growth of gene and cell therapy pipelines in the cancer area by pharmaceutical and biotechnology companies, especially as candidates move from pre-clinical research to clinical and commercial manufacture. This demand is also being fueled by rising use of tailored and targeted cancer medicines.

Plasmid DNA Manufacturing Market- Geographical Insights

North America dominates the market. One of the major growth drivers is the high and increasing cancer burden and growing interest in gene treatments, cell therapies, cancer vaccines and other novel biotherapeutics that use plasmid DNA as a critical input in their production process. In 2025, the National Cancer Institute estimates there will be 2,041,910 new cancer cases and 618,120 cancer deaths in the United States. Meanwhile, Canadian Cancer Statistics predicts that there will be 254,800 new cancer cases and 87,400 cancer deaths in Canada in 2025. This huge cancer burden is making pharmaceutical and biotech companies to ramp up their oncology focused gene and cell therapy pipeline which in turn is driving the requirement for high purity and GMP-grade plasmid DNA for manufacturing viral vectors and genetic engineering.

US Plasmid DNA Manufacturing Market- Country Insights

The US holds a majority of market share. One of the major drivers for this growth is the huge investment made by the leading pharmaceutical and biotech companies in development and manufacturing of gene and cell therapy which is leading to an increasing demand for high-quality plasmid DNA as a critical component in the production of viral vectors and genetic engineering. For instance, Novartis announced in April 2025 that it would invest $23 billion over five years in its U.S. manufacturing and research and development footprint including expanding capabilities supporting advanced therapies. Its U.S. network already includes a gene-therapy manufacturing facility in Durham, North Carolina.

Plasmid DNA Manufacturing Market- Competitive Landscape:

Plasmid DNA manufacturing market is moderately consolidated with several key players and highly competitive, with competition focused on GMP manufacturing capacity, scale, quality of products, regulatory know-how, turn around time and end-to-end services. Key players include Charles River Laboratories, Danaher (Aldevron), Lonza, Thermo Fisher Scientific, GenScript ProBio, VGXI, Catalent, AGC Biologics, WuXi AppTec, Eurogentec, Kaneka, VectorBuilder.

Recent Developments:

In August 2026, 4basebio PLC, a specialist in enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO), announced an expanded, non-exclusive collaboration providing drug developers access to 4basebio's Research Use Only, High-Quality, and GMP-grade hpDNA(R) development and clinical programs. Through the collaboration, Genezen will offer access to 4basebio's synthetic DNA developed specifically for viral vector applications, creating a more streamlined path for cell and gene therapy developers to advance programs toward the clinic.

In January 2026, Bionova Scientific LLC, an Asahi Kasei company and a bespoke CDMO, has announced a strategic manufacturing alliance with Syenex, a genetic medicines platform company. The collaboration is focused on expanding global access to plasmid DNA used in next-generation gene delivery for advanced cell and gene therapies. Under the agreement, Bionova Scientific will serve as the preferred manufacturing partner for Syenex's delivery platforms. The partnership builds on Bionova's plasmid DNA manufacturing capabilities, which support lentiviral vector production and DNA templates for mRNA manufacturing. The companies said the alliance addresses ongoing challenges in pricing, quality, and supply-chain reliability of plasmid DNA.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Lonza
  • Charles River Laboratories
  • Thermo Fisher Scientific
  • AGC Biologics
  • GenScript ProBio
  • Aldevron (Danaher)
  • Cobra Biologics (Charles River)
  • Catalent
  • WuXi AppTec
  • WuXi Advanced Therapies
  • Eurogentec
  • Sartorius (BIA Separations)
  • PharmaCell
  • ProBio
  • Pharmaron
  • Esco Aster
  • AGTC (Applied Genetic Technologies Corp.)
  • VGXI (GeneOne Life Science)
  • PlasmidFactory
  • VectorBuilder
  • Others

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY GRADE- MARKET ANALYSIS, 2020 - 2033

  • R&D Grade
  • Viral Vector Development
  • AAV
  • Lentivirus
  • Adenovirus
  • Retrovirus
  • Others
  • mRNA Development
  • Antibody Development
  • DNA Vaccine Development
  • Others
  • GMP Grade

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY DEVELOPMENT PHASE- MARKET ANALYSIS, 2020 - 2033

  • Pre-Clinical Therapeutics
  • Marketed Therapeutics
  • Clinical Therapeutics

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • DNA Vaccines
  • Immunotherapy
  • Cell & Gene Therapy
  • Others

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033

  • Genetic Disorder
  • Cancer
  • Infectious Disease
  • Others

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Plasmid DNA Manufacturing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Plasmid DNA Manufacturing Market Snippet by Grade
    • 2.1.2. Plasmid DNA Manufacturing Market Snippet by Development Phase
    • 2.1.3. Plasmid DNA Manufacturing Market Snippet by Application
    • 2.1.4. Plasmid DNA Manufacturing Market Snippet by Disease
    • 2.1.5. Plasmid DNA Manufacturing Market Snippet by Country
    • 2.1.6. Plasmid DNA Manufacturing Market Snippet by Region
  • 2.2. Competitive Insights

3. Plasmid DNA Manufacturing Key Market Trends

  • 3.1. Plasmid DNA Manufacturing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Plasmid DNA Manufacturing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Plasmid DNA Manufacturing Market Opportunities
  • 3.4. Plasmid DNA Manufacturing Market Future Trends

4. Plasmid DNA Manufacturing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Plasmid DNA Manufacturing Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Plasmid DNA Manufacturing Market Landscape

  • 6.1. Plasmid DNA Manufacturing Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Plasmid DNA Manufacturing Market - By Grade

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Grade, 2025 & 2033 (%)
    • 7.1.2. R&D Grade
      • 7.1.2.1. Viral Vector Development
      • 7.1.2.1.1. AAV
      • 7.1.2.1.2. Lentivirus
      • 7.1.2.1.3. Adenovirus
      • 7.1.2.1.4. Retrovirus
      • 7.1.2.1.5. Others
      • 7.1.2.2. mRNA Development
      • 7.1.2.3. Antibody Development
      • 7.1.2.4. DNA Vaccine Development
      • 7.1.2.5. Others
    • 7.1.3. GMP Grade

8. Plasmid DNA Manufacturing Market - By Development Phase

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Development Phase, 2025 & 2033 (%)
    • 8.1.2. Pre-Clinical Therapeutics
    • 8.1.3. Marketed Therapeutics
    • 8.1.4. Clinical Therapeutics

9. Plasmid DNA Manufacturing Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 9.1.2. DNA Vaccines
    • 9.1.3. Immunotherapy
    • 9.1.4. Cell & Gene Therapy
    • 9.1.5. Others

10. Plasmid DNA Manufacturing Market - By Disease

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Disease, 2025 & 2033 (%)
    • 10.1.2. Genetic Disorder
    • 10.1.3. Cancer
    • 10.1.4. Infectious Disease
    • 10.1.5. Others

11. Plasmid DNA Manufacturing Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Plasmid DNA Manufacturing Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Plasmid DNA Manufacturing Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Plasmid DNA Manufacturing Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Grade, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Development Phase, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Plasmid DNA Manufacturing Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Lonza
    • 12.2.2. Charles River Laboratories
    • 12.2.3. Thermo Fisher Scientific
    • 12.2.4. AGC Biologics
    • 12.2.5. GenScript ProBio
    • 12.2.6. Aldevron (Danaher)
    • 12.2.7. Cobra Biologics (Charles River)
    • 12.2.8. Catalent
    • 12.2.9. WuXi AppTec
    • 12.2.10. WuXi Advanced Therapies
    • 12.2.11. Eurogentec
    • 12.2.12. Sartorius (BIA Separations)
    • 12.2.13. PharmaCell
    • 12.2.14. ProBio
    • 12.2.15. Pharmaron
    • 12.2.16. Esco Aster
    • 12.2.17. AGTC (Applied Genetic Technologies Corp.)
    • 12.2.18. VGXI (GeneOne Life Science)
    • 12.2.19. PlasmidFactory
    • 12.2.20. VectorBuilder
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기